Vav3 oncogene is upregulated and a poor prognostic factor in breast cancer patients

Chen,Xin; Chen,Si; Liu,Xiao‑An; Zhou,Wen‑Bin; Ma,Rui‑Rui; Chen,Lin

doi:10.3892/ol.2015.3004

Vav3 oncogene is upregulated and a poor prognostic factor in breast cancer patients

Authors:
- Xin Chen
- Si Chen
- Xiao‑An Liu
- Wen‑Bin Zhou
- Rui‑Rui Ma
- Lin Chen
View Affiliations

Affiliations: Department of Breast Surgery, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China, Department of General Surgery, Songjiang Central Hospital, Shanghai 201699, P.R. China
Published online on: March 2, 2015 https://doi.org/10.3892/ol.2015.3004
Pages: 2143-2148

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The Vav3 oncogene is overexpressed and has a significant role in the tumorigenesis of prostate cancer and glioblastoma. In the present study, the expression status and prognostic value of Vav3 expression was investigated in breast cancer. Vav3 protein levels were analyzed by immunoblotting in human breast cancer and epithelial cell lines. Immunohistochemistry was used to detect Vav3 in a tissue microarray of 173 breast cancers and 19 benign breast lesions. Statistical analysis was performed to reveal the association between Vav3 expression and clinicopathological parameters. Disease‑free survival (DFS) and overall survival (OS) were calculated by Kaplan‑Meier analysis and the Cox regression model. The Vav3 protein level was higher in the breast cancer cell lines than in the normal human breast cells. Vav3 was expressed in 86.1% of breast cancer patients, but in only 15.6% patients with benign breast disease. Patients with negative estrogen receptor expression, axillary lymph node involvement and a high tumor-node-metastasis stage demonstrated a higher positive rate of Vav3 expression. The Kaplan‑Meier survival analysis revealed that patients with higher Vav3 expression exhibited shorter DFS and OS times. The multivariate Cox analysis revealed that Vav3 was a prognostic factor of survival. Overall, Vav3 was overexpressed in human breast cancer cells and this correlated with a shorter survival time, indicating that Vav3 is a biomarker of a poor prognosis for breast cancer patients.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
2	Bustelo XR: The VAV family of signal transduction molecules. Crit Rev Oncog. 7:65–88. 1996. View Article : Google Scholar : PubMed/NCBI
3	Van Aelst L and D'Souza-Schorey C: Rho GTPases and signaling networks. Genes Dev. 11:2295–2322. 1997. View Article : Google Scholar : PubMed/NCBI
4	Katzav S, Martin-Zanca D and Barbacid M: vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells. EMBO J. 8:2283–2290. 1989.PubMed/NCBI
5	Zugaza JL, Lopez-Lago MA, Caloca MJ, Dosil M, Movilla N and Bustelo XR: Structural determinants for the biological activity of Vav proteins. J Biol Chem. 277:45377–45392. 2002. View Article : Google Scholar : PubMed/NCBI
6	Bustelo XR: Regulatory and signaling properties of the Vav family. Mol Cell Biol. 20:1461–1477. 2000. View Article : Google Scholar : PubMed/NCBI
7	Lyons LS and Burnstein KL: Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity. Mol Endocrinol. 20:1061–1072. 2006. View Article : Google Scholar : PubMed/NCBI
8	Dong Z, Liu Y, Lu S, et al: Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer. Mol Endocrinol. 20:2315–2325. 2006. View Article : Google Scholar : PubMed/NCBI
9	Rosenblatt AE, Garcia MI, Lyons L, et al: Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer. Endoc Relat Cancer. 18:207–219. 2011.
10	Loss LA, Sadanandam A, Durinck S, et al: Prediction of epigenetically regulated genes in breast cancer cell lines. BMC Bioinformatics. 11:3052010. View Article : Google Scholar : PubMed/NCBI
11	Sauter G, Simon R and Hillan K: Tissue microarrays in drug discovery. Nat Rev Drug Discov. 2:962–972. 2003. View Article : Google Scholar : PubMed/NCBI
12	Torhorst J, Bucher C, Kononen J, et al: Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol. 159:2249–2256. 2001. View Article : Google Scholar : PubMed/NCBI
13	Nocito A, Bubendorf L, Tinner EM, et al: Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol. 194:349–357. 2001. View Article : Google Scholar : PubMed/NCBI
14	Moch H, Schraml P, Bubendorf L, et al: High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol. 154:981–986. 1999. View Article : Google Scholar : PubMed/NCBI
15	Kononen J, Bubendorf L, Kallioniemi A, et al: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 4:844–847. 1998. View Article : Google Scholar : PubMed/NCBI
16	Salhia B, Tran NL, Chan A, et al: The guanine nucleotide exchange factors trio, Ect2 and Vav3 mediate the invasive behavior of glioblastoma. Am J Pathol. 173:1828–1838. 2008. View Article : Google Scholar : PubMed/NCBI
17	Zeng L, Sachdev P, Yan L, et al: Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase activity, modulates cell morphology and induces cell transformation. Mol Cell Biol. 20:9212–9224. 2000. View Article : Google Scholar : PubMed/NCBI
18	Palmby TR, Abe K, Karnoub AE and Der CJ: Vav transformation requires activation of multiple GTPases and regulation of gene expression. Mol Cancer Res. 2:702–711. 2004.PubMed/NCBI
19	Hunter SG, Zhuang G, Brantley-Sieders D, Swat W, Cowan CW and Chen J: Essential role of Vav family guanine nucleotide exchange factors in EphA receptor-mediated angiogenesis. Mol Cell Biol. 26:4830–4842. 2006. View Article : Google Scholar : PubMed/NCBI
20	Fang WB, Brantley-Sieders DM, Hwang Y, Ham AJ and Chen J: Identification and functional analysis of phosphorylated tyrosine residues within EphA2 receptor tyrosine kinase. J Biol Chem. 283:16017–16026. 2008. View Article : Google Scholar : PubMed/NCBI
21	Vollenweider-Zerargui L, Barrelet L, Wong Y, Lemarchand-Beraud T and Gomez F: The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women. Clinical correlation on 547 patients. Cancer. 57:1171–1180. 1986. View Article : Google Scholar : PubMed/NCBI
22	Viale G, Regan MM, Maiorano E, et al: Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1–98. J Clin Oncol. 25:3846–3852. 2007. View Article : Google Scholar : PubMed/NCBI
23	Altan E and Altundag K: Clinical and pathological characteristics of occult breast cancer and review of the literature. J BUON. 16:434–436. 2011.PubMed/NCBI
24	Colleoni M, Rotmensz N, Robertson C, et al: Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol. 13:273–279. 2002. View Article : Google Scholar : PubMed/NCBI